Pilot Randomized Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Depression in Patients with Non-Metastatic Breast Cancer (Depression)
Sponsor: |
Columbia University Velocity Grant |
Enrolling: |
Male and Female Patients |
Study Length: |
12 Weeks |
IRB Number: |
8209 |
U.S. Govt. ID: |
NCT04973930 |
Contact: |
Alexandra Mackay: 646-774-8027 / alexandra.mackay@nyspi.columbia.edu |
The goal of this research study is to compare evidence-based tele-therapies for patients with non-metastatic breast cancer and comorbid major depression. Participants will be randomly assigned (like by the flip of a coin) to receive twelve weeks of either interpersonal therapy (IPT) or pharmacotherapy with a serotonin reuptake inhibitor, either venlafaxine XR (Effexor) or escitalopram (Lexapro). All sessions will be held virtually via Zoom. Participants will be assessed by independent evaluators and will complete self-report questionnaires throughout the study. There will be a blood sample collected at the beginning and end of the study to measure C-reactive protein, a marker of inflammation elevated in both breast cancer and depression. Participants will be offered $50 compensation as a token of thanks for completing the final evaluation at Week 12.
This study is closed
Investigator
John Markowitz, MD
Are you currently depressed? |
Yes |
No |
Have you been diagnosed with non-metastatic breast cancer in the last 10 years? |
Yes |
No |
Do you have access to a smart phone, tablet, or computer with a camera and reliable internet connection? |
Yes |
No |
Are you currently receiving treatment for depression? |
Yes |
No |